Sanofi and Regeneron Pharmaceuticals have expanded their immunology partnership in a deal valued at up to $8 billion. Sanofi will pay Regeneron $1 billion upfront and up to $7 billion in milestone payments to co-develop four next-generation antibody candidates. The deal helps Sanofi bolster its pipeline ahead of patent expiration for their blockbuster drug Dupixent. The companies also settled prior litigation and will split future costs and profits equally.
Structure of the expanded partnership
- ▪Sanofi and Regeneron Pharmaceuticals' expanded alliance adds four next-generation, early-stage antibody drug candidates invented by Regeneron Pharmaceuticals that target immune signals driving inflammation
- ▪Under the expanded immunology partnership between Sanofi and Regeneron Pharmaceuticals, Regeneron Pharmaceuticals will lead research and development, Sanofi will lead global sales, and the companies will split costs and profits equally
- ▪Sanofi and Regeneron Pharmaceuticals announced an agreement on October 1, 2026 to expand their partnership to co-develop and co-commercialize new immunology drugs
- ▪Regeneron Pharmaceuticals secured an option to join Sanofi's experimental drug lunsekimig once lunsekimig's late-stage trials for chronic obstructive pulmonary disease are finished
Debatable claims
- ▪Major pharmaceutical companies should prioritize internal R&D over external co-development partnerships
- ▪Sanofi's partnership expansion is an effective way to address its upcoming Dupixent patent cliff
- ▪Sanofi's $1 billion upfront payment for early-stage candidates is an unjustified financial risk
Story comments
Loading comments…